SITE002-0018

SITE002 (USA) › SITE002-0018

SITE002-0018

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE002 (USA) · Dr. Nolan
consented 2025-09-12

enrolled

AEs

2

Serious

0

Dropout signal

–

Adverse events

2

Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-12-09 (study day 262); relationship: not assessed

moderate assessed

Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-11-12 (study day 235); relationship: not assessed

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.